AC Forum TRAIN Pharmacy Grant Spring 2023
Days Left
to Enter

The TRAIN Pharmacy Grant will award each institution $120,000 over a 2-year period. The goal of this grant is to support the institution in developing the new program, as well as provide salary assistance for two consecutive residency years.

The AC Forum awarded four 2-year grants in 2022 and will award four additional 2-year grants in 2023.

The portal for applications in the Spring 2023 cycle will close May 15, 2023. Awardees will be announced by or before June 30, 2023.


Applicants must be US-based organizations with existing ASHP-accredited pharmacy residency programs and advanced pharmacy practices in the prevention and treatment of thrombosis and bleeding.

The Residency Program Director (RPD) must have either 1) completed a PGY2 residency in a related specialty area and have 3+ years of practice experience OR 2) have 5 years of practice experience in a relevant specialty area. The RPD should also be board certified in either Pharmacotherapy, Ambulatory Care, or Cardiology or have obtained recognition as a Certified Anticoagulation Care Provider from the National Certification Board for Anticoagulation Providers. The Director must also actively practice in a clinical area involving anticoagulation management.

Each awarded residency program will select the PGY2 resident via their own selection process, using their own criteria such as clinical excellence, academic potential, leadership ability, teaching skills, and demonstrated interest in thrombosis and hemostasis-related care. The AC Forum recommends that diversity, equity, and inclusion be prioritized as part of the selection process at each institution.

Grant Application Process (Spring 2023 Application Cycle)

Sites will be asked to provide the following in the application:

  • Program contact information
  • List of current PGY2 pharmacy residencies
  • Candidate recruitment plan
  • Budget breakdown
  • Program description that includes:
    • Brief curriculum outline and learning experiences offered
    • The institution’s current service(s) in thrombosis and hemostasis management
    • The pharmacy department’s involvement in managing thrombosis & hemostasis
    • Potential preceptors to be involved in residency training (include a short bio of each faculty member)
    • Research opportunities for the resident
  • Letter of support from the Director of Pharmacy
  • Letter of support from a physician champion with a practice focus in thrombosis and hemostasis


Review Process & Notification

Applications are due May 15, 2023.

Institutions will be selected by an Anticoagulation Forum Review Committee and will be selected based on their ability to train well-rounded residents, their clinical and research expertise in relevant areas, and the program’s focus on thrombosis and hemostasis management. Reviewers with a conflict of interest will be recused from reviewing the specific application. Selected institutions will be notified of grant awards by or before June 30, 2023 and will be required to sign a Grant Agreement with the Anticoagulation Forum.

Questions the Review Committee will consider, include:

  • Does the program have faculty that can provide robust training?
  • What is the likelihood strong residents will apply/accept the program?
  • What types of research opportunities exist for/within the program?
  • How does the pharmacy department drive thrombosis and hemostasis clinical initiatives?
  • What is the likelihood the resident will have an impact in the field?
  • What is the likelihood of job placement after residency?